Big Pharma Immunotherapy May Kill You In A Month

In 2015, Teri received a diagnosis of liver cirrhosis stemming from undiagnosed Hepatitis C. Over the subsequent three years, she developed inflammatory bowel symptoms, edema, and diverticulitis. By mid-2022, a severe edema flare-up prompted Teri to consult with her internist and GI doctors, leading to the discovery of a liver tumor. Teri embarked on a strict diet rich in lean proteins and vegetables to alleviate inflammation, which yielded improvement in her condition. Feeling stronger in January 2023, she opted to follow her GI doctor's recommendation and commenced Genentech’s immunotherapy regimen, aimed at impeding tumor blood supply. However, following her initial infusion on January 30, 2023, Teri experienced a devastating hemorrhage within a week, indicating the treatment's ineffectiveness and its harmful impact.

Prior to treatment, Teri had only two tumors, yet post-treatment, an additional fifteen tumors were detected. This difference occurred in the 15 days post treatment. The negligence lies in the failure of Teri’s primary care provider, Kaiser Permanente, to consider Teri's risk factors, which, would have rendered her ineligible to receive this treatment. Furthermore, it has come to light that Genentech's claimed mortality rate of 2.4% within the first month on the protocol inadequately accounts for additional causes of death, reflecting mortality directly attributable to the treatment itself. There is no data on using the protocol with a compromised immune system. Further, had we known the risk factors were well over 2.4%, we would not have elected to engage in the treatment.

The treatment used on Teresa was TECENTRIQ® (atezolizumab) + Avastin® (bevacizumab).

The purpose of this information is to determine if you, or a loved one, has been negatively or fatally impacted by Genentech’s TECENTRIQ® (atezolizumab) + Avastin® (bevacizumab) therapy and if you are interested in joining my legal action.

If you are interested, please provide your email address and phone number below so you can be contacted. 

If you would rather contact me directly, call 707-484-5669.

Thank you for your consideration.